DEVELOPMENT AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS

淀粉样 B 蛋白寡聚化抑制剂

• 批准号: 7112795
• 负责人: GAL BITAN
• 金额: $ 24.74万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7112795
• 关键词: Alzheimer' s disease; amyloid proteins; amyloidosis; cell line; chemical structure function; circular dichroism; combinatorial chemistry; drug design /synthesis /production; inhibitor /antagonist; mass spectrometry; molecular pathology; neurofibrillary tangles; neurons; neuropathology; neuropharmacology; neurotoxins; oligopeptides; organic brain syndrome; protein folding; proteolysis

We hypothesize that soluble amyloid beta-protein (Abeta) oligomers are key effectors of neurotoxicity and may be a primary cause of Alzheimer's disease (AD). Consequently, inhibition of Abeta Oligomerization is an attractive strategy for preventing and treating AD. We propose to use a systematic, rational design approach for preparation and structure-activity studies of Abeta Oligomerization inhibitors. We will focus our efforts on inhibitors of early Abeta(1-42) oligomers termed "paranuclei." We choose early Abeta(1-42) oligomers as our primary target because Abeta(1-42) is particularly linked to AD and because inhibition of early assembly of Abeta(1-42) will alleviate the neurotoxic effects, both of the oligomers themselves and of the larger neurotoxic assemblies, protofibrils and fibrils, for which paranuclei are precursors. Our design in based on recent experimental and modeling data that delineate structural features of paranucleus assembly, including primary-quaternary structure relationships and conformation of the C-terminus of Abeta(1-42). This region is responsible directly for the enhanced toxicity and distinct Oligomerization pattern of Abeta(1-42) relative to the more abundant alloform, Abeta(1-40). The inhibitor design process is tightly integrated with the structural and biological projects within the overall Program. The design process not only will benefit from the structural data generated by the Program members, but also will feed back into structural studies and provide further understanding of how particular regions and residues in Abeta interact with each other to form oligomers.

我们假设可溶性淀粉样β蛋白（Abeta）寡聚体是神经毒性和神经毒性的关键效应物。 可能是阿尔茨海默病（AD）的主要原因。因此，Abeta 寡聚化的抑制 是预防和治疗 AD 的一种有吸引力的策略。我们建议使用系统的、合理的 Abeta 寡聚抑制剂的制备和结构活性研究的设计方法。我们 我们将集中精力研究被称为“副核”的早期 Abeta(1-42) 寡聚体的抑制剂。我们选择早 Abeta(1-42) 寡聚物作为我们的主要目标，因为 Abeta(1-42) 与 AD 特别相关，并且因为 抑制 Abeta(1-42) 的早期组装将减轻两种寡聚物的神经毒性作用 其本身以及较大的神经毒性组件、原纤维和原纤维，其中核旁是 前体。我们的设计基于最近描述结构的实验和建模数据 核旁组装的特征，包括一级-四级结构关系和 Abeta(1-42) C 末端的构象。该区域直接负责增强 相对于更丰富的同种异形体，Abeta(1-42) 的毒性和独特的寡聚模式， 阿贝塔（1-40）。抑制剂设计过程与结构和生物学项目紧密结合 在总体计划内。设计过程不仅会受益于结构数据 由计划成员生成，而且还将反馈到结构研究中并提供 进一步了解 Abeta 中的特定区域和残基如何相互作用形成 低聚物。